Search Results - "Burris, Howard A."

Phase II Study of Capecitabine in Combination With Thalidomide in Patients With Metastatic Breast Cancer.

Authors: Burris, Howard A. Jones, Suzanne F. Shipley, Dianna et al.

Source: Cancer Investigation. Jun2010, Vol. 28 Issue 4, p408-412. 5p. 3 Charts, 2 Graphs.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Authors: Powles, Thomas Eder, Joseph Paul Petrylak, Daniel P. et al.

Source: Nature. 11/27/2014, Vol. 515 Issue 7528, p558-562. 5p.

Subjects: Metastasis, Bladder cancer treatment, Cancer chemotherapy, Somatic mutation, Antigens

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.

Authors: Brown, Jacqueline Scardo, Savannah Method, Michael et al.

Source: BMC Cancer. Dec2022, Vol. 22 Issue 1, p1-20. 20p.

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.

Authors: Miele, Evelina Abballe, Luana Spinelli, Gian Paolo et al.

Source: BMC Cancer. 2/17/2020, Vol. 20 Issue 1, p1-10. 10p. 4 Charts, 4 Graphs.

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

Authors: LoRusso, Patricia M. Infante, Jeffrey R. Kim, Kevin B. et al.

Source: BMC Cancer. 3/6/2017, Vol. 17, p1-13. 13p. 1 Diagram, 4 Charts, 1 Graph.

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.

Authors: Burris, Howard A. Lebrun, Fabienne Rugo, Hope S. et al.

Source: Cancer (0008543X). May2013, Vol. 119 Issue 10, p1908-1915. 8p.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Authors: Perez, Edith A. de Haas, Sanne Lysbet Eiermann, Wolfgang et al.

Source: BMC Cancer. 6/24/2019, Vol. 19 Issue 1, pN.PAG-N.PAG. 1p. 1 Chart, 1 Graph.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Authors: Perez, Edith A. de Haas, Sanne Lysbet Eiermann, Wolfgang et al.

Source: BMC Cancer. 5/30/2019, Vol. 19 Issue 1, p1-14. 14p. 1 Diagram, 4 Charts, 2 Graphs.

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

Authors: Shapiro, Geoffrey I. Kristeleit, Rebecca S. Burris, Howard A. et al.

Source: Clinical Pharmacology in Drug Development. Jan2019, Vol. 8 Issue 1, p107-118. 12p.

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Authors: Worst, Thomas S. Weis, Cleo-Aron Stöhr, Robert et al.

Source: Scientific Reports. 9/26/2018, Vol. 8 Issue 1, p1-11. 11p.

A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma.

Authors: Hainsworth, John D. Infante, Jeffrey R. Spigel, David R. et al.

Source: Cancer Investigation. Aug2011, Vol. 29 Issue 7, p451-455. 5p. 2 Charts, 1 Graph.

Referee Acknowledgement for 2010.

Source: British Journal of Cancer. 6/7/2011, Vol. 104 Issue 12, p1945-1950. 6p.

A Phase I Trial to Determine the Safety of Imatinib in Combination With Vatalanib in Patients With Advanced Malignancies.

Authors: Spigel, David Jones, Suzanne Hainsworth, John et al.

Source: Cancer Investigation. May2011, Vol. 29 Issue 4, p308-312. 5p. 3 Charts.

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer.

Authors: Yardley, Denise A. McCleod, Michael Schreiber, Fred et al.

Source: Cancer Investigation. Oct2010, Vol. 28 Issue 9, p925-931. 7p. 4 Charts, 2 Graphs.

Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Authors: Hainsworth, John D. Burris III, Howard A. Erland, Joan B. et al.

Source: Cancer Investigation. Apr2003, Vol. 21 Issue 2, p193-199. 7p. 3 Charts.

Emerging therapeutic agents for advanced non-small cell lung cancer.

Authors: Chen, Ruqin Manochakian, Rami James, Lauren et al.

Source: Journal of Hematology & Oncology. 5/24/2020, Vol. 13 Issue 1, p1-23. 23p.

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.

Authors: Wang, Hao Kaur, Gurbakhash Sankin, Alexander I. et al.

Source: Journal of Hematology & Oncology. 6/11/2019, Vol. 12 Issue 1, p1-20. 20p.

Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.

Authors: Jouali, Farah Marchoudi, Nabila Talbi, Salwa et al.

Source: BMC Cancer. 9/18/2018, Vol. 18 Issue 1, p1-6. 6p. 1 Chart.

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.

Authors: Kaufman, Peter A. Bloom, Kenneth J. Burris, Howard et al.

Source: Cancer (0008543X). Sep2014, Vol. 120 Issue 17, p2657-2664. 9p.

Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.

Authors: Pal, Sumanta K. Bajorin, Dean Dizman, Nazli et al.

Source: Cancer (0008543X). Jun2020, Vol. 126 Issue 11, p2597-2606. 10p.